Clone features of patients with CH that developed hematologic malignancy over the course of the study
| Patient ID . | Number of mutations . | Mutation . | Maximum VAF . | High risk gene . | Average VAF . | Type of malignancy . |
|---|---|---|---|---|---|---|
| 0004 | 4 | TET2 R1516X | 0.398 | No | 0.217 | MDS |
| TET2 Q695X | 0.369 | No | ||||
| SRSF2 P95H | 0.177 | Yes | ||||
| JAK2 V617F | 0.02 | Yes | ||||
| 1060 | 1 | SF3B1 R625C | 0.241 | Yes | 0.236 | MDS |
| 1073 | 4 | TET2 Q742X | 0.422 | No | 0.237 | CMML |
| SRSF2 P95R | 0.330 | Yes | ||||
| TET2 Y1245Lfs∗22 | 0.270 | No | ||||
| TET2 N535Kfs∗6 | 0.033 | No | ||||
| 1096 | 1 | TET2 G1288D | 0.796 | No | 0.758 | CMML |
| 2026 | 1 | TP53 Y220C | 0.676 | Yes | 0.676 | AML |
| 2038 | 1 | TET2 Q749Rfs∗15 | 0.021 | No | 0.021 | MDS |
| Patient ID . | Number of mutations . | Mutation . | Maximum VAF . | High risk gene . | Average VAF . | Type of malignancy . |
|---|---|---|---|---|---|---|
| 0004 | 4 | TET2 R1516X | 0.398 | No | 0.217 | MDS |
| TET2 Q695X | 0.369 | No | ||||
| SRSF2 P95H | 0.177 | Yes | ||||
| JAK2 V617F | 0.02 | Yes | ||||
| 1060 | 1 | SF3B1 R625C | 0.241 | Yes | 0.236 | MDS |
| 1073 | 4 | TET2 Q742X | 0.422 | No | 0.237 | CMML |
| SRSF2 P95R | 0.330 | Yes | ||||
| TET2 Y1245Lfs∗22 | 0.270 | No | ||||
| TET2 N535Kfs∗6 | 0.033 | No | ||||
| 1096 | 1 | TET2 G1288D | 0.796 | No | 0.758 | CMML |
| 2026 | 1 | TP53 Y220C | 0.676 | Yes | 0.676 | AML |
| 2038 | 1 | TET2 Q749Rfs∗15 | 0.021 | No | 0.021 | MDS |
Clone features considered to be high-risk include total number of mutations, VAF, and mutation(s) in high-risk genes.
AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; MDS, myelodysplastic syndrome.